Minerva Neurosciences Inc Common Stock (NERV)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham-style investor, I start with what I can know. Minerva is a clinical-stage biotech with no reported revenue, seven employees, and a lead candidate, roluperidone, in a Phase 3 confirmatory trial for negative symptoms of schizophrenia. That is a binary profile: the investment case rests on a clinical and regulatory outcome, not on a durable competitive moat. The filed numbers are volatile. In fiscal year 2023, the year ended 2023-12-31, net loss was $30.0M and diluted EPS was -$4.61. In fiscal year 2024, the year ended 2024-12-31, net income was $1.4M and diluted EPS was $0.19. In fiscal year 2025, the year ended 2025-12-31, net loss ballooned to $293.4M and diluted EPS was -$34.67. In fiscal Q1 2026, the quarter ended 2026-03-31, net loss was $125.4M and diluted EPS was -$2.86; in fiscal Q2 2026, the quarter ended 2026-06-30, net income was $17.5M but diluted EPS was -$0.14. Those swings make normalized earnings power impossible to estimate. Trailing-twelve-month free cash flow is -$26.2M, a -21.8% FCF yield on a $120.1M market cap at the 2026-10-13 close of $2.52. FairStock's calculations at that close show a P/E of -0.07, ROCE -28.42%, Piotroski 1/9, Altman Z -10.54, and a FairStock score of 13/100. The Lynch category is TURNAROUND—loss in latest year after earlier profits—but I see no margin of safety in a pre-revenue biotech. Without an approved product or predictable cash flows, this is speculation on science. I would watch trial data, cash burn, and financing needs, not quarterly EPS noise.

In plain English: Minerva Neurosciences is a very small drug developer with no product sales. It is testing a medicine for schizophrenia symptoms and has only a handful of employees. The company is losing money and burning cash, and the share price looks based on hope for trial success rather than current business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer